• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性肺癌术后复发:解剖-临床和治疗研究。

Postoperative recurrence of primary lung cancer: anatomo-clinical and therapeutic study.

出版信息

Tunis Med. 2021;99(5):560-568.

PMID:35244906
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8772599/
Abstract

BACKGROUND

Lung cancer is the leading cause of cancer mortality worldwide. Even after radical resection, the rate of recurrence of non-small cell lung cancer remains high.

AIM

To identify the profile of patients operated for lung cancer and to study the prognostic factors of tumor recurrence.

METHODS

We performed a retrospective study including 67 cases of lung cancer with curative surgery, hospitalized between 2010 and 2016.

RESULTS

The mean age was 61 years. The sex ratio was 21. The average time to diagnosis was 22 days. The average time to start treatment was 10 days. The most common histological type was adenocarcinoma (63%). Lobectomy was performed in 63% of the patients. Tumor recurrence was noted in 40% of the patients. The average time between recurrence and the surgical treatment was 12 months. The most common location of recurrence was the lung (70%). Recurrence was more common among adenocarcinoma and smokers older than 60 years. The majority of locally advanced and metastatic cancers have recurred. The average survival was 56 ± 4months. Better survival rates were observed in young patients, with less than 25 pack-years of early-stage, no lymph node involvement, and patients who received adjuvant chemotherapy. The probability of survival was 5 years for all tumor stages.

CONCLUSION

The prognostic factors for recurrence after radical resection for lung cancer were: the age of patients, smoking history, histological type, tumor stage, and surgical procedure.

摘要

背景

肺癌是全球癌症死亡的主要原因。即使进行根治性切除,非小细胞肺癌的复发率仍然很高。

目的

确定接受肺癌手术治疗患者的特征,并研究肿瘤复发的预后因素。

方法

我们进行了一项回顾性研究,纳入了 2010 年至 2016 年间接受根治性手术治疗的 67 例肺癌患者。

结果

平均年龄为 61 岁,男女比例为 21。平均诊断时间为 22 天,平均开始治疗时间为 10 天。最常见的组织学类型是腺癌(63%)。63%的患者接受了肺叶切除术。40%的患者出现肿瘤复发。复发与手术治疗之间的平均时间为 12 个月。最常见的复发部位是肺部(70%)。腺癌和 60 岁以上的吸烟者更易复发。大多数局部晚期和转移性癌症已经复发。平均生存时间为 56±4 个月。年轻患者、早期 25 包年以下吸烟史、无淋巴结受累以及接受辅助化疗的患者生存率更好。所有肿瘤分期的 5 年生存率为 50%。

结论

根治性切除术后肺癌复发的预后因素包括:患者年龄、吸烟史、组织学类型、肿瘤分期和手术方式。

相似文献

1
Postoperative recurrence of primary lung cancer: anatomo-clinical and therapeutic study.原发性肺癌术后复发:解剖-临床和治疗研究。
Tunis Med. 2021;99(5):560-568.
2
[The prognostic impact of preoperative PET-CT on postoperative recurrence for completely resected stage I non-small cell lung cancer].[术前PET-CT对完全切除的Ⅰ期非小细胞肺癌术后复发的预后影响]
Zhonghua Wai Ke Za Zhi. 2015 Jul 1;53(7):502-7.
3
Preoperative bronchoscopic cancer confirmation does not increase risk of recurrence in stage1A non-small cell lung cancer.术前支气管镜检查确诊癌症并不会增加ⅠA期非小细胞肺癌的复发风险。
Gen Thorac Cardiovasc Surg. 2018 May;66(5):284-290. doi: 10.1007/s11748-018-0909-y. Epub 2018 Mar 21.
4
[Recurrence and survival after surgical treatment of lung cancer].[肺癌手术治疗后的复发与生存情况]
Tidsskr Nor Laegeforen. 2010 Jan 14;130(1):25-8. doi: 10.4045/tidsskr.09.0689.
5
Recurrence Risk Factors Analysis for Stage I Non-small Cell Lung Cancer.I期非小细胞肺癌复发风险因素分析
Medicine (Baltimore). 2015 Aug;94(32):e1337. doi: 10.1097/MD.0000000000001337.
6
Early Distant Recurrence in Patients With Resected Stage I Lung Cancer: A Case Series of "Blast Metastasis".根治性切除术后 I 期肺癌患者的早期远处复发:“爆炸转移”病例系列。
Clin Lung Cancer. 2021 Jan;22(1):e132-e135. doi: 10.1016/j.cllc.2020.09.002. Epub 2020 Sep 18.
7
Surgery for young patients with lung cancer.年轻肺癌患者的手术治疗。
Lung Cancer. 2003 Nov;42(2):215-20. doi: 10.1016/s0169-5002(03)00286-1.
8
Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma.新国际肺癌研究协会/美国胸科学会/欧洲呼吸学会肺腺癌分类对完全切除的 I 期肺腺癌患者死亡和复发的预后价值。
Ann Surg. 2013 Dec;258(6):1079-86. doi: 10.1097/SLA.0b013e31828920c0.
9
Non-small cell lung cancer in surgically treated women.接受手术治疗的女性非小细胞肺癌
Tumori. 2013 Nov-Dec;99(6):661-6. doi: 10.1177/030089161309900604.
10
Clinicopathological characteristics and surgical results of lung cancer patients aged up to 50 years: the Japanese Lung Cancer Registry Study 2004.50 岁以下肺癌患者的临床病理特征和手术结果:日本肺癌登记研究 2004 年报告。
Lung Cancer. 2014 Feb;83(2):246-51. doi: 10.1016/j.lungcan.2013.11.007. Epub 2013 Nov 17.

引用本文的文献

1
Clinical, humanistic and economic burden associated with recurrence among patients with early-stage cancers: a systematic literature review.早期癌症患者复发相关的临床、人文和经济负担:一项系统文献综述
Front Oncol. 2025 May 26;15:1575813. doi: 10.3389/fonc.2025.1575813. eCollection 2025.
2
Trim13-induced ubiquitination of RPS27A inhibits the progression of lung cancer by depending on the inactivation of NF-κB signaling pathway.Trim13诱导的RPS27A泛素化通过依赖NF-κB信号通路的失活来抑制肺癌进展。
Physiol Rep. 2024 Dec;12(23):e70157. doi: 10.14814/phy2.70157.
3
S100A16 stabilizes the ITGA3‑mediated ECM‑receptor interaction pathway to drive the malignant properties of lung adenocarcinoma cells via binding MOV10.S100A16 通过结合 MOV10 稳定 ITGA3 介导的细胞外基质-受体相互作用通路,从而驱动肺腺癌细胞的恶性特性。
Mol Med Rep. 2025 Jan;31(1). doi: 10.3892/mmr.2024.13376. Epub 2024 Oct 25.
4
F-FDG PET/CT radiomics for prediction of lymphovascular invasion in patients with early stage non-small cell lung cancer.用于预测早期非小细胞肺癌患者淋巴管侵犯的F-FDG PET/CT影像组学
Front Oncol. 2023 Jul 21;13:1185808. doi: 10.3389/fonc.2023.1185808. eCollection 2023.
5
Identification and validation of molecular subtype and prognostic signature for lung adenocarcinoma based on neutrophil extracellular traps.基于中性粒细胞胞外陷阱的肺腺癌分子亚型和预后标志物的鉴定和验证。
Pathol Oncol Res. 2023 Apr 18;29:1610899. doi: 10.3389/pore.2023.1610899. eCollection 2023.
6
CT-derived body composition associated with lung cancer recurrence after surgery.基于 CT 的身体成分与手术后肺癌复发相关。
Lung Cancer. 2023 May;179:107189. doi: 10.1016/j.lungcan.2023.107189. Epub 2023 Apr 8.
7
Polo-like kinase (PLK) 5, a new member of the PLK family, serves as a biomarker to indicate anabatic tumor burden and poor prognosis for resectable non-small cell lung cancer.Polo样激酶(PLK)5是PLK家族的新成员,作为一种生物标志物,提示可切除的非小细胞肺癌患者肿瘤进展及预后不良。
Front Surg. 2023 Jan 6;9:964044. doi: 10.3389/fsurg.2022.964044. eCollection 2022.

本文引用的文献

1
[Therapeutic strategies in patients undergoing surgery for non-small cell lung cancer. Results of the ESCAP-2011-CPHG study, promoted by the French College of General Hospital Respiratory Physicians (CPHG)].[非小细胞肺癌手术患者的治疗策略。由法国综合医院呼吸内科医师学会(CPHG)推动的ESCAP - 2011 - CPHG研究结果]
Rev Mal Respir. 2017 Nov;34(9):976-990. doi: 10.1016/j.rmr.2017.05.002. Epub 2017 Nov 15.
2
[First treatment strategies in the 2 years following lung cancer diagnosis. ESCAP-2011-CPHG, a real-life study carried out in French general hospitals].[肺癌诊断后2年内的初始治疗策略。ESCAP - 2011 - CPHG,一项在法国综合医院开展的真实世界研究]
Rev Mal Respir. 2017 Nov;34(9):991-999. doi: 10.1016/j.rmr.2017.10.001. Epub 2017 Oct 27.
3
[Current knowledge on perioperative treatments of non-small cell lung carcinomas].[关于非小细胞肺癌围手术期治疗的当前知识]
Rev Mal Respir. 2017 Jun;34(6):618-634. doi: 10.1016/j.rmr.2016.12.001. Epub 2017 Jul 12.
4
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.诱导化疗联合放化疗治疗 IIIA/N2 期非小细胞肺癌:一项 3 期随机试验。
Lancet. 2015 Sep 12;386(9998):1049-56. doi: 10.1016/S0140-6736(15)60294-X. Epub 2015 Aug 11.
5
Recurrence Risk Factors Analysis for Stage I Non-small Cell Lung Cancer.I期非小细胞肺癌复发风险因素分析
Medicine (Baltimore). 2015 Aug;94(32):e1337. doi: 10.1097/MD.0000000000001337.
6
Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data.非小细胞肺癌的术前化疗:一项个体参与者数据的系统评价和荟萃分析。
Lancet. 2014 May 3;383(9928):1561-71. doi: 10.1016/S0140-6736(13)62159-5. Epub 2014 Feb 25.
7
[Epidemiology and incidence of primary lung cancer in a region with low tobacco consumption: Guadeloupe (French West Indies). Data from the cancer registry 2008-2009].[烟草低消费地区原发性肺癌的流行病学与发病率:瓜德罗普岛(法属西印度群岛)。2008 - 2009年癌症登记数据]
Rev Mal Respir. 2013 Sep;30(7):537-48. doi: 10.1016/j.rmr.2013.01.010. Epub 2013 Feb 28.
8
Segmentectomy versus wedge resection for non-small cell lung cancer in high-risk operable patients.肺段切除术与楔形切除术治疗高危可手术非小细胞肺癌。
Ann Thorac Surg. 2013 Nov;96(5):1747-54; discussion 1754-5. doi: 10.1016/j.athoracsur.2013.05.104. Epub 2013 Aug 30.
9
Radical sublobar resection for small-diameter lung cancers.小直径肺癌的亚肺叶切除术。
Thorac Surg Clin. 2013 Aug;23(3):301-11. doi: 10.1016/j.thorsurg.2013.04.003. Epub 2013 May 10.
10
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.早期和局部晚期非小细胞肺癌(NSCLC):ESMO临床实践指南之诊断、治疗及随访
Ann Oncol. 2013 Oct;24 Suppl 6:vi89-98. doi: 10.1093/annonc/mdt241. Epub 2013 Jul 16.